Prostacyclin modulates the systemic inflammatory response in traumatic brain injury: a randomised clinical study
(English)In: Article in journal (Other academic) Submitted
Systemic inflammatory response is common in patients with severe traumatic brain injury (TBI), and may contribute to a less favourable outcome. The aim was to evaluate the effect of prostacyclin on systemic inflammation.
This study is part of a prospective, randomised, clinical trial on the effect of prostacyclin (epoprostenol, Flolan®) in patients with severe TBI. Epoprostenol/placebo was given during 72 hours and then de-escalated. Interleukin-6, interleukin-8, soluble intracellular adhesion molecules-1 (sICAM-1) and C-reactive protein (CRP) were sampled daily.
46 patients were included and randomised to 23 of each group (epoprostenol/placebo). Interleukin-6 was statistically lower within 96 hours (p = 0.04), and CRP within 96 and 120 hours (p = 0.04 and p = 0.008 respectively) after trauma in the epoprostenol group compared to the placebo group. No significant differences were detected between the groups in the levels of interleukin-8 and sICAM-1 or in outcome.
Administration of the prostacyclin analogue epoprostenol, compared to placebo significantly decreased interleukin-6 and CRP levels in patients with severe TBI. The beneficial effect of this decrease is further to investigate.
traumatic brain injury, prostacyclin, interleukin-6, C-reactive protein, interleukin-8, intracellular adhesion molecules
Anesthesiology and Intensive Care
Research subject Anaesthesiology
IdentifiersURN: urn:nbn:se:umu:diva-21054OAI: oai:DiVA.org:umu-21054DiVA: diva2:210550